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grafts was substantially lower (AOR  0.61, P  0.04) whenVascular access use in Europe and the United States: Results
surgery trainees assisted or performed access placements.from the DOPPS.
When used as a patient’s first access, AVF survival was superiorBackground. A direct broad-based comparison of vascular
to grafts regarding time to first failure (RR 0.53, P 0.0002),access use and survival in Europe (EUR) and the United States
and AVF survival was longer in EUR compared with the US(US) has not been performed previously. Case series reports
(RR 0.49, P 0.0005). AVF and grafts each displayed bettersuggest that vascular access practices differ substantially in the
survival if used when initiating HD compared with being usedUS and EUR. We report on a representative study (DOPPS)
after patients began dialysis with a catheter.which has used the same data collection protocol for 6400
Conclusion: Large differences in vascular access use existhemodialysis (HD) patients to compare vascular access use at
between EUR and the US, even after adjustment for patient145 US dialysis units and 101 units in five EUR countries
(France, Germany, Italy, Spain, and the United Kingdom). characteristics. The results strongly suggest that a facility’s pref-
Methods. Logistic analysis evaluated factors associated with erences and approaches to vascular access practice are major
native arteriovenous fistula (AVF) versus graft use or perma- determinants of vascular access use.
nent access versus catheter use for prevalent and incident HD
patients. Times to failure for AVF and graft were analyzed
using Cox proportional hazards regression.
Vascular access use is an integral and important aspectResults. AVF was used by 80% of EUR and 24% of US prev-
of hemodialysis treatments provided for patients withalent patients, and was significantly associated with younger
age, male gender, lower body mass index, non-diabetic status, end-stage renal disease (ESRD). Two types of perma-
lack of peripheral vascular disease, and no angina. After ad- nent accesses are used in hemodialysis: (1) native arterio-
justing for these factors, AVF versus graft use was still much
venous fistulas (AVF) that are formed from a patient’shigher in EUR than US (AOR  21, P  0.0001). AVF use
endogenous vasculature, and (2) grafts that are createdwithin facilities varied from 0 to 87% (median 21%) in the
US, and 39 to 100% (median 83%) in EUR. For patients who using either synthetic material or bovine vessels. For
were new to HD, access use was: 66% AVF in EUR versus some practitioners, synthetic grafts are desired for ease
15% in US (AOR  39, P  0.0001), 31% catheters in EUR of cannulation [1], shorter maturation times, and use-vs. 60% in US, and 2% grafts in EUR vs. 24% in US. In
fulness when a patient’s vascular anatomy does not af-addition, 25% of EUR and 46% of US incident patients did
ford construction of an AVF. However, AVF are viewednot have a permanent access placed prior to starting HD. In
EUR, 84% of new HD patients had seen a nephrologist for as being superior to grafts due to the much small number
30 days prior to ESRD compared with 74% in the US (P  of procedures associated with AVF use, and longer over-
0.0001); pre-ESRD care was associated with increased odds of
all survival [2]. Furthermore, initial results reported byAVF versus graft use (AOR 1.9, P 0.01). New HD patients
Dhingra et al suggest a lower mortality risk for prevalenthad a 1.8-fold greater odds (P  0.002) of starting HD with a
permanent access if a facility’s typical time from referral to diabetic patients when dialyzing with an AVF compared
access placement was 2 weeks. AVF use when compared to to a graft (abstract; J Am Soc Nephrol 11:182A, 2000).
It has been reported that vascular access use among
chronic hemodialysis (HD) patients differs between theKey words: arteriovenous fistula, grafts, vascular access, pre-ESRD
care, hemodialysis, end-stage renal disease, catheter, DOPPS. United States (US) and Europe based on results of sev-
eral regional studies [3–7]. However, no representativeReceived for publication December 15, 2000
comparison of vascular access practice in Europe andand in revised form July 19, 2001
Accepted for publication August 27, 2001 the US has been performed. The present study uses data
from the Dialysis Outcomes and Practice Patterns Study 2002 by the International Society of Nephrology
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(DOPPS) to examine vascular access use in the US and in which AVF are compared to grafts, synthetic grafts
and bovine grafts were combined together to form thefive European countries (France, Germany, Italy, Spain,
and the United Kingdom). DOPPS is a prospective, lon- “graft” group. Bovine grafts comprised 3 to 4% of all
grafts used by HD patients in the US and EUR.gitudinal study of hemodialysis practices and associated
outcomes. Facilities and patients are selected to provide
Description of cross-sectional and incidentnationally representative samples of the HD population
patient samplesin each country as described previously [8]. The same
data collection protocol is used in all countries allowing The types of vascular access in use were described for
the cross-section of all patients (prevalent) enrolled ata direct comparison of outcomes across countries and
types of facilities. the start of the study and for new (incident) HD patients
enrolled anytime during the study. Patients were classi-The goals of the present investigation were to (1) com-
pare the frequencies of vascular access types used by fied as incident patients if their study enrollment date
was within five days of their first HD treatment forHD patients in the US and the five European countries,
(2) examine patient and practice pattern characteristics ESRD. For the incident samples in the US and EUR,
greater than 90% of patients were on dialysis for onethat may influence vascular access use, (3) compare na-
tive arteriovenous fistula (AVF) and graft survival in day or less when entering DOPPS. Therefore, the access
in use at study start for these patients is equivalent tothe US and Europe, and (4) determine differences in
placement of temporary vascular accesses for incident the access used for the patient’s first HD treatment.
patients in the US and Europe.
Statistical analysis
Predictors of access use. Logistic regression was used
METHODS
to model the patient characteristics associated with the
Data sources type of access used for HD at the time of study entry.
Three different outcomes were considered: (1) AVF ver-Data for these analyses were restricted to ESRD pa-
tients, older than 17 years of age, receiving in-center he- sus graft use among prevalent patients, (2) AVF versus
graft use among incident HD patients at time of studymodialysis, hemofiltration, or hemodiafiltration at 145
dialysis facilities in the United States (US), 21 facilities entry, and (3) permanent vascular access versus catheter
use among incident patients at time of study entry. Inin Germany, and 20 facilities each in France, Italy, Spain,
and the United Kingdom (UK). The five European coun- the case of AVF versus graft comparisons, other access
types were excluded from the analyses. Predictors oftries are collectively referred to as Europe (EUR) in this
paper. Although these five countries do not represent all type of access are indicated in the Results section for
each model.European HD practice, they account for approximately
84% of all HD patients in the European Union according Access survival analyses. Cox proportional hazards re-
gression was used to model time to first vascular accessto a recent report of the European Renal Registry and
National Registries for the year 1995 [9]. failure among incident HD patients. Time to failure was
calculated as the time from first use until first failure.United States data for this analysis were collected from
July 1996 to October 2000, and data from EUR were gath- Failure was defined as any reported event (such as throm-
bosis) that resulted in an access no longer able to functionered from July 1998 to October 2000. Nationally repre-
sentative samples were obtained using randomized pa- for HD, even though the access may be usable at a later
time if successfully salvaged by subsequent declotting ortient selection with ongoing longitudinal data collection
as described previously [8]. revision procedures. Observations were censored when
a patient departed from the facility or the last day ofVascular access data were collected for each patient
at entry into the study and updated whenever a vascular known access follow-up. Models were adjusted for the
following covariates: age, gender, diabetes mellitus, pe-access-related event occurred. Vascular access informa-
tion included type of access, placement location, creation ripheral vascular disease, body mass index, and continent
(that is, EUR vs. US). For particular comparisons, mod-date, date of first use, and dates of failure. Vascular access-
related infections or procedures were also recorded. els based on data subsets were used. For example, AVF
versus graft survival was compared only in US patients,
Classification of vascular access types and EUR versus US comparisons were restricted to AVF
because there were too few grafts in EUR to generateVascular accesses were reported as one of six types:
native arteriovenous fistula (AVF), synthetic graft, bo- meaningful event rates.
For plotting all survival curves, survival estimates forvine graft, tunneled central vein catheter, untunneled
temporary catheter, or other type. Temporary catheters EUR were made relative to the US mean values for the
covariates of age, gender, diabetes mellitus, peripheralwere defined as any type or brand of uncuffed, percuta-
neously placed, central vein dialysis catheter. In analyses vascular disease, and body mass index so that all survival
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Table 2. Anteriovenous fistula (AVF), graft, and catheter useTable 1. Demographic characteristics and baseline comorbidities of
a cross-sectional sample of patients in the United States (US) and among prevalent and incident hemodialysis (HD) patients in
Europe (EUR) and the United States (US)Europe (EUR) at study start
US EUR Access use for prevalent Access use for incident
HD patients HD patientsCovariates (N3882) (N2597) P value
AVF Grafts Catheters AVF Grafts CathetersAge years, mean 60.515.5a 60.715.2a 0.78
Female % 47 43 0.03
US 24 58 17 15 24 60Blacks % 38 1 0.0001
EUR 80 10 8 66 2 31Diabetes mellitus % 46 22 0.0001
France 77 15 6 62 2 36Diabetes mellitus as primary
Germany 84 12 4 83 1 15cause of ESRD % 41 17 0.0001
Italy 90 4 5 60 0 38Peripheral vascular disease % 23 19 0.005
Spain 82 12 7 71 5 24Body mass index kg/m2, mean 25.15.9a 24.14.7a 0.0001
UK 67 9 22 47 2 50History of angina pectoris % 37 25 0.0001
US (N3813), US (N2179),Years on HD, mean 3.4 5.1 0.0001
EUR (N2455) EUR (N875)
EUR values were weighted according to the number of HD patients in each
The distribution of AVF, grafts, and catheters is shown separately for prevalentcountry divided by the total number of hemodialysis (HD) patients in the 5
and incident HD patients in the US, EUR, and the countries comprising EUR.EUR countries based on information in [9].
Catheters include both tunneled and untunneled central vein catheters. Valuesa Standard deviation; P values are for the comparison between US and EUR
for EUR, if weighted by the proportion of HD patients in each country, were
found to be very similar to the unweighted values shown in the table below.
Access use by incident patients is at the time of initiating HD. AVF were placed
in the lower arm for 74% of US prevalent patients and 79% of EUR prevalent
patients. For incident patients, tunneled catheters comprised 25% of catheters in
curves are comparable, and differences between curves EUR and 52% of catheters in the US. For prevalent patients, tunneled catheters
comprised 69% of catheters in EUR and 59% of catheters in the US.are attributable to factors other than the covariates.
Graphic analyses confirmed the validity of the propor-
tional hazards assumption.
All statistical analyses were performed using SAS ver- Table 3. Adjusted odds ratios for the probability of arteriovenous
fistula (AVF) versus graft use among prevalent hemodialysis (HD)sion 6.12. Logistic regression analyses employed the
patients in Europe (EUR) and the United States (US)GENMOD procedure with a binomial error distribution
Covariate AORa P valueand logit link function. Facility clustering effects in logis-
tic regression models were accounted for using a “re- Female versus male 0.40 0.0001
Peripheral vascular disease (yes vs. no) 0.68 0.0001peated” statement specifying facility-level clustering and
Diabetes mellitus (yes vs. no) 0.76 0.0007an exchangeable correlation matrix. Cox regression anal- History of angina pectoris (yes vs. no) 0.80 0.006
yses employed the PHREG procedure. Facility cluster- Age (for every 10 years older) 0.89 0.0001
BMI kg/m2 (for every 3 unit increase) 0.92 0.0001ing effects in these analyses were addressed using robust
Per year on HD 0.99 0.18standard error estimates based on the sandwich estima- EUR versus US 21 0.0001
tor [10] with an independent working correlation.
a AOR, adjusted odds ratio of AVF versus graft use; BMI, body mass index;
(N  4849)
AOR values1.0 indicate that the covariate is associated with increased odds
of AVF use.RESULTS
Vascular access use among prevalent HD patients in
EUR and the US
Demographic and comorbid characteristics at the time very similar to the values reported for the 1997 US popu-
lation of in-center HD patients by the U.S. Renal Dataof study entry are shown in Table 1 for a cross-sectional
sample of HD patients in EUR and the US. The US was System [11]. Comparable information is not available
for EUR from other published sources.significantly (P  0.05) different from EUR with regard
to all listed comorbid and demographic characteristics, The pattern of vascular access use among prevalent
HD patients revealed much greater utilization of AVFexcept for age (P  0.78). Because of these differences
in patient mix between EUR and the US, these demo- in EUR compared with the US (Table 2). In EUR, AVF
accounted for 80% of all accesses, with 10% of patientsgraphic and comorbid characteristics were included as
covariates in adjusted models of vascular access use. using grafts. High AVF use was seen in all five EUR coun-
tries, ranging from 67% in the United Kingdom to 90%Differences between the US and EUR also were seen in
the proportion of patients with hypertension, myocardial in Italy. In contrast, grafts were the predominant access
type in the US, comprising 58% of all accesses, with 24%infarction, congestive heart failure, and chronic obstruc-
tive pulmonary disease, but these comorbidities were not of US patients using an AVF. Catheter use was 17% in
the US compared with 8% in EUR (P  0.0001).found to be significantly related to vascular access use
among prevalent patients. The values for age, diabetes A logistic model was used to evaluate patient charac-
teristics associated with AVF versus graft use in preva-mellitus as primary cause of ESRD, and proportion of
female and black patients in the US-DOPPS sample are lent HD patients in EUR and the US (Table 3). AVF
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Fig. 1. Arteriovenous fistula (AVF) use among
prevalent patients in Europe (EUR) and the
United States (US) for patient groups (A) with-
out diabetes, peripheral vascular disease, (PVD),
and coronary artery disease (CAD). (B) Pa-
tients with diabetes, PVD, and/or CAD. The
percent of patients using an AVF at the time
of study enrollment in a cross-sectional sample
of patients was determined for the two sub-
groups shown.
use was found to be strongly related (P 0.01) to younger versus graft use is associated with certain patient charac-
teristics, but a large difference remains in AVF use be-age, male gender, non-diabetic status, lower body mass
index, no history of angina, and absence of peripheral tween the US and EUR that is not accounted for by
differences in these patient characteristics.vascular disease (PVD). Although the probability of
AVF use was not associated with the number of years Arteriovenous fistulae use among prevalent patients
was also compared in EUR and the US for two patientof HD treatment when analyzed across all countries
(AOR  0.99, P  0.18), a continent-specific analysis subgroups with different levels of associated comorbidity
(Fig. 1). The first subgroup consisted of non-diabeticindicated that years of HD treatment had opposite ef-
fects upon AVF use in EUR (AOR  0.93 for every patients, age 18 to 54 years old, without peripheral vascu-
lar disease and without coronary artery disease. In EUR,year of HD, P 0.0001) compared with the US (AOR
1.02 for every year of HD, P 0.04). Allon et al recently 76% of females and 89% of males in this subgroup were
using an AVF compared with 41% of US males and 22%showed AVF use for prevalent patients in the US HEMO
study to be significantly related to these characteristics, of US females. The second subpopulation consisted of
diabetic patients, 54 years of age, who have peripheralexcept angina, which was not tested [12]. The HEMO
study also showed coronary artery disease to be signifi- vascular disease and/or coronary artery disease. AVF
use was high for this group of patients in EUR, rangingcantly related to AVF use. Our analysis found that coro-
nary artery disease (CAD) was significantly associated from 64% for females to 82% for males. However in the
US, only 22% of males and 10% of females used anwith AVF use if history of angina was excluded from
the model (AOR  0.85, P  0.03), but CAD was not AVF in this group. The results of the subpopulation
analysis demonstrate that the high level of AVF use insignificant if angina was included in the model (AOR 
0.96, P  0.63). Therefore, the effect of coronary artery EUR is seen both for patients of low or high comorbidity
levels. AVF use in the US is substantially lower thandisease on AVF use is explained by the angina variable
in our analytical model. EUR, even for relatively young, non-diabetic patients
without coronary artery disease.The above analysis model also indicated that the likeli-
hood of AVF versus graft use was much greater in EUR The percentage of AVF use in different dialysis units
in each country was also determined (Fig. 2). EUR dial-than in the US (AOR  21, P  0.0001). Parameter
estimates obtained from a similar logistic model re- ysis units displayed a range of AVF use, varying from
39% in some facilities to 100% in others, with a medianstricted to EUR practice were applied to the US patient
mix, and estimated that 79% of US patients would be facility value of 83% AVF use. In EUR, 31% of dialysis
units had an AVF use rate of 90%, with 100% ofexpected to use an AVF if the EUR practice of access
placement was applied to the US patient mix of age, patients using an AVF in 25% of Italian dialysis units.
US dialysis units displayed rates as low as 0% AVF usegender, diabetes mellitus, peripheral vascular disease,
body mass index, history of angina, and years on HD. in some dialysis units but as high as 87% in other facili-
ties, with a median facility value of 21% AVF use. TheseIn conclusion, the analytical models indicate that AVF
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Fig. 2. Distribution of arteriovenous fistula
(AVF) use among facilities within Europe
(EUR) and the United States (US). The per-
cent of patients using an AVF was determined
for a cross-sectional sample of patients within
each DOPPS dialysis unit in EUR and the US.
The distribution of AVF use within facilities is
shown separately for the US ( ) and EUR
( ), and is shown in increments of 5%. The
following percentiles of each distribution are
provided for the 10th, 25th, 50th (median), 75th,
and 90th percentiles.
Table 4. Amount of time prior to end-stage renal disease (ESRD) that patients are first seen by a nephrologist in Europe (EUR) and the
United States (US), as reported by the study coordinator or by patients
EUR US
Data source Type of pre-ESRD care % of incident patients P value
Study coordinator Patient seen by nephrologist 30 days prior to ESRD 84 74 0.0001
Patient Patient seen by nephrologist 30 days prior to ESRD 87 80 0.0001
Patient Patient seen by nephrologist 4 months prior to ESRD 80 68 0.0001
Patient Patient seen by nephrologist 1 year prior to ESRD 69 44 0.0001
In US, N  1813 for the Study Coordinator analysis, and N  1015 for the Patient analysis. In EUR, N  888 for the Study Coordinator analysis, and N  706
for the Patient analysis.
results indicate that despite a moderately low overall use an AVF when starting HD. In contrast, 60% of US inci-
of AVF in the US, some facilities have achieved a high dent patients began dialysis with a catheter, with only
rate of AVF use comparable to that seen for many EUR 15% using an AVF and 24% using a graft.
facilities. However, one-quarter of US dialysis units had Pre-ESRD care was compared between EUR and the
very low AVF use in which only 0 to 12% of patients US to determine its effect upon access use at the start
dialyzed with an AVF within each of these units. In the of HD (Table 4). Data from facility staff indicated that
HEMO study, Allon et al recently indicated a similar 84% of EUR patients and 74% of US patients had seen
large variation of 12 to 61% AVF use for 15 university- a nephrologist30 days prior to ESRD. Patients reported
affiliated clinical centers in the US [12]. a similar pattern of moderately greater short-term pre-
ESRD care provided by EUR dialysis units. However,
Vascular access use among patients new patient responses also indicated a substantially larger
to hemodialysis proportion of EUR patients receiving long term pre-
ESRD care, with 69% of EUR patients seeing a nephrol-Similar to the prevalent patient sample, large differ-
ogist for at least one year prior to ESRD compared withences were seen in AVF use by new (incident) HD pa-
44% in the US.tients in the US compared with EUR. AVF were used by
Various relationships between early nephrologic care66% of incident HD patients in EUR when starting HD,
and the type of access used by incident patients when start-with 2% of EUR incident patients using a graft (Ta-
ing HD were examined. For patients receiving nephro-ble 2). In four of the five EUR countries, AVF use ranged
logic care30 days prior to ESRD, 79% of EUR patientsfrom 60 to 83% among new HD patients, whereas in the
United Kingdom 47% of incident patients dialyzed with and 48% of US patients (P  0.0001) used a permanent
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Table 5. Adjusted odds ratios for the probability of arteriovenous fistula (AVF) versus graft use, or permanent access versus temporary
access use in incident patients at start of hemodialysis (HD) in Europe (EUR) and the United States (US)
Model b: Permanent access
Model a: AVF versus graft usea versus temporary access useb
Covariate AOR P value AOR P value
Age for every 10 years older 0.92 0.14 1.06 0.07
Female vs. male 0.39 0.0001 0.82 0.05
Diabetes mellitus (yes vs. no) 0.97 0.84 1.14 0.19
PVD (yes vs. no) 0.80 0.35 0.92 0.53
History of angina (yes vs. no) 0.97 0.85 0.81 0.04
Pre-ESRD care (yes vs. no) 1.95 0.01 6.1 0.0001
If time from referral to access
placement is 2 weeksc (yes vs. no) 0.87 0.57 1.76 0.002
If time from AVF creation until first
cannulation is 2 monthsc (yes vs. no) 1.24 0.31 0.87 0.46
Number of surgeons placing permanent
accesses in a dialysis unitc (for every
3 surgeon increase) 1.00 0.98 1.15 0.10
If surgery trainees perform/assist in
placing permanent accessc (yes vs. no) 0.61 0.04 0.83 0.30
EUR versus US 39 0.0001 4.8 0.0001
PVD is peripheral vascular disease; Pre-ESRD care refers to whether patient saw a nephrologist 30 days prior to ESRD; logistic models were adjusted for facility
clustering effects.
a Model (a), AOR values 1.0 indicate increased odds of AVF use; N  967
b Model (b), AOR values 1.0 indicate increased odds of permanent access use; N  2073
c Denotes a facility level characteristic provided by the study coordinator at each dialysis unit
access for their first HD treatment (data not shown). ripheral vascular disease, history of angina, pre-ESRD
care 30 days prior to ESRD, time from referral toThis result indicates that EUR pre-ESRD practice is
substantially more successful than US pre-ESRD prac- access creation, typical time until AVF are first cannu-
lated, use of surgery trainees, or the number of surgeonstice in establishing a permanent access that is functional
for a patient’s first HD treatment, even though a large placing permanent vascular accesses for patients in a
dialysis unit.proportion of EUR patients start HD with an AVF.
Furthermore, 46% of US incident patients and 25% of Permanent access versus temporary access compari-
sons revealed that permanent vascular access use at startEUR incident patients did not have a permanent access
placed prior to starting dialysis, even though 55% of of HD is greater in EUR than in the US (AOR  4.8,
P 0.0001) and is less likely for female patients (AORthese patients in both EUR and the US had seen a
nephrologist 30 days prior to ESRD (data not shown). 0.82, P  0.05) or for patients having a history of angina
(AOR 0.81, P 0.04; Table 5). In addition, permanentA logistic model was used to evaluate the relationships
of various patient characteristics and treatment practices access use at the start of HD was substantially more
likely if patients were treated in a dialysis unit that typi-upon AVF versus graft use by new ESRD patients when
starting HD (Table 5). AVF use was significantly less cally creates an access within two weeks of referral
(AOR 1.76, P 0.002) or if patients saw a nephrologistlikely if patients were female (AOR 0.39, P  0.0001)
or if surgery trainees assisted or performed vascular ac- 30 days prior to ESRD (AOR  6.1, P  0.0001).
Subgroup analyses were used to explore access use incess placements for the dialysis unit (AOR  0.61, P 
0.04). Patient age, diabetes, peripheral vascular disease, EUR versus US further. Three different incident HD pa-
tient subpopulations were analyzed (Fig. 3). The firsthistory of angina, a facility’s usual time from referral
to access placement, a facility’s typical time from AVF two groups were non-diabetic white males of (group i)
age 18 to 54 years, or (group ii) age 54 years, and thecreation until first cannulation, and number of surgeons
were not significantly related to whether patients began third group was white diabetic females 17 years old
(group iii). The race restriction was used to make com-HD with an AVF versus a graft. However, AVF use was
substantially more likely than graft use if patients received parisons across continents more easily, and the relatively
smaller number of patients in the diabetic female sub-nephrologic care30 days prior to ESRD (AOR 1.95,
P  0.01) or if treated in EUR compared to the US group limited further division of this subgroup into dif-
ferent age categories. The results of this analysis indicate(AOR 39, P 0.0001). This latter result indicates that
there continues to be a large difference in AVF versus that in the US, AVF use among the two incident male
non-diabetic groups was 24% and 19%, respectively, andgraft use among incident patients in EUR and US even
after adjustment for age, gender, diabetes mellitus, pe- decreased to 11% for incident female diabetic patients.
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Fig. 3. Arteriovenous fistula (AVF) use among
incident patients in Europe (EUR) and the
United States (US) for three different patient
groups. The percent of white patients, who
were new to HD and using an AVF at study
start was determined for the three groups. Val-
ues of n refer to the total number of patients
in the particular subgroup.
In contrast, AVF use was high for all three groups in nantly accounted for by Italian nephrologists, who com-
prised 96% of all nephrologists placing accesses amongEUR, ranging from 63% for diabetic females to 77%
for non-diabetic males aged 18 to 54 years. incident patients in the study sample.
In the above analysis, grafts accounted for 0.5% of
Permanent vascular access survival in theall accesses among EUR non-diabetic males and 4% of
US and EURaccesses among EUR diabetic females. In contrast for
the US, 18% of non-diabetic males and 25% of diabetic Cox regression analyses adjusted for case-mix were
females used grafts when starting HD. These results fur- used to assess AVF and graft survival among incident
ther indicate that grafts are seldom used as the choice patients in EUR and the US. The AVF versus graft
of a permanent access for incident patients in EUR, even survival in Figure 4A is for incident patients who used
among diabetic female patients. either a graft or AVF for their first HD treatment. The
estimated one-year survival probability was 68% for
Type of physician placing permanent vascular accesses AVF (95% CI 59 to 77%, N  177) and 49% for grafts
(95% CI 42 to 57%, N  251) in the US, with AVF inCountry variation was observed concerning the type
of physician who generally places permanent vascular EUR displaying a one year survival of 83% (95% CI 
78 to 89%, N  429). The case-mix adjusted survivalaccesses for HD patients. In France, Germany, Spain,
the UK, and the US, 65 to 89% of permanent vascular curves indicated substantially better survival of AVFs
compared with grafts in the US [risk ratios (RR) ofaccesses were placed by a vascular surgeon. However,
in Italy, approximately 80% of permanent access place- failure  0.56, P  0.0009]. In addition, AVF survival
was found to be greater in EUR than in the US (RR ofments were performed by a nephrologist, similar to the
recent report by Bonucchi et al [6]. Logistic models of failure 0.49 in EUR versus US, P 0.0003). The small
number of grafts placed among EUR incident patientsAVF versus graft use at start of HD did not find a signifi-
cant relationship between AVF use and the type of physi- precluded a survival analysis of grafts for EUR. Regard-
ing other covariates tested in a model of AVF survival,cian placing the permanent vascular access with regard to
vascular surgeons, general surgeons, transplant surgeons, peripheral vascular disease (RR  3.2, P  0.001) and
female gender (RR  2.3, P  0.003) were associatedor urologists (P value range, 0.48 to 0.55 depending on
physician type, data not shown). However, if a nephrolo- with increased risk of AVF failure in EUR, with periph-
eral vascular disease possibly related to increased AVFgist was the primary type of physician placing permanent
vascular accesses for patients in a dialysis unit, then 100% failure also within the US (RR  1.7, P  0.12).
Whereas the above analysis indicates better survivalof incident patients who began HD with a permanent
access were found to use an AVF in these units (N  74 of AVF compared with grafts for patients who start HD
with a permanent access, the pattern of AVF versus graftpatients). This latter practice of high AVF use associated
with access placement by nephrologists was predomi- survival is more complex if patients use a temporary
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Fig. 4. (A) Survival function of arteriovenous
fistula (AVF) versus graft survival in United
States (US) and Europe (EUR) for incident
patients using a permanent vascular access at
study start. Access survival estimates were ob-
tained from Cox regression analysis stratified
by access type, and adjusted for patient age,
gender, diabetes mellitus, peripheral vascular
disease, and body mass index (N  430 for
EUR, N  428 for US). The small number of
grafts among EUR incident patients pre-
cluded a survival analysis for grafts in EUR.
(B) Survival function of AVF versus graft sur-
vival in US and EUR for incident patients
starting HD with a temporary vascular access.
Analysis is restricted to incident patients start-
ing HD with a temporary access but focuses
upon survival of the first permanent access
used by the patient thereafter. Access survival
estimates were obtained from Cox regression
analysis stratified by access type, and adjusted
for patient age, gender, diabetes mellitus, pe-
ripheral vascular disease, and body mass index
(N  164 for EUR, N  209 for US). The
small number of grafts among EUR incident
patients precluded a survival analysis for grafts
in EUR.
catheter for their first HD treatment and then the sur- would each decrease by 3% points with no change in
graft survival, resulting in a small increase of 6 to 7% invival of a subsequently used AVF or graft is determined.
In this situation, no significant difference was observed the risk ratios of failure for AVF versus grafts in the
US, and AVF in EUR versus the US.in AVF versus graft survival in the US during the first
240 days of use (RR of failure 0.76, P 0.24), whereas
Sites of catheter placementafter this time period AVF displayed substantially better
long-term survival compared with grafts (Fig. 4B). The site where catheters were placed was compared
for incident patients in EUR and the US (Fig. 5). InBoth in EUR and the US, AVF survival was substan-
tially better when AVF were used for the first HD treat- EUR, the internal jugular vein was the most commonly
used site, serving for 57% of untunneled catheters andment compared with AVF first used after starting HD
with a catheter (in EUR, RR of failure  0.50, P  80% of tunneled catheters. In addition, 15 to 18% of
EUR catheters were placed in the subclavian vein. In0.001; in US, RR of failure  0.63, P  0.03, if AVF was
used for first HD treatment). In addition, graft survival in the US, the subclavian vein (46%) and internal jugular
vein (46%) were the most commonly used sites for un-the US was better if used for the first HD treatment
versus grafts used after starting HD with a catheter (RR tunneled catheters, with tunneled catheters placed pre-
dominantly in the internal jugular vein (62%) and theof failure  0.70, P  0.03).
For the above survival analyses, elective angioplasty subclavian vein (36%).
Since DOPPS data collection in the US has occurredwas not included as an indication of access failure. How-
ever, a sensitivity analysis demonstrated that if elective over the time period from 1996 through 2000, a time
trend analysis was performed. It indicated that subcla-angioplasty had been included as a failure, then the one-
year AVF survival probabilities in the US and EUR vian vein placement of catheters has decreased in the
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for the US are similar to those reported by Woods and
Port [13] and Stehman-Breen et al [14].
A major question addressed during these analyses was
what are the predominant factors associated with access
use? Patient age, gender, diabetes, peripheral vascular
disease, body mass index, and history of angina were
found to be associated with access use in EUR and the
US. However, after adjustment for these patient charac-
teristics, large differences are still seen in AVF use be-
tween the US and EUR. Instead, a facility’s preference
for type of access [15], and approach to vascular access
and nephrologic care appear to be important factors de-
termining access placement. For example, early nephro-
logic care is similar in the US and EUR, with 84% of
EUR patients seeing a nephrologist 30 days prior to
ESRD compared to 74% of US patients. Despite this
similarity, the percentage of US patients starting HD
with a permanent access is nearly one-half that of pa-
tients in EUR. In addition, for new patients receiving
nephrologic care for 30 days prior to ESRD, the per-
centage starting HD with a permanent access was 79%
in EUR compared with 48% in the US. This large differ-
ence exists despite the US practice of placing more grafts
Fig. 5. (A) Distribution of placement locations for untunneled tempo- than AVF, with grafts generally perceived to mature in
rary catheters used by incident patients at start of hemodialysis (HD)
a shorter time. Arora et al reported a similar observationin Europe (EUR) and the United States (US). (N  204 for EUR, N 
for a group of US patients who had seen a nephrologist628 for US). (B) Distribution of placement locations of tunneled central
vein catheters used by incident patients at start of HD in EUR and the for more than four months, with only 40% of these pa-
US. (N  71 for EUR, N  683 for US).
tients using a permanent vascular access for their first
HD treatment [16].
The large difference between EUR and the US in the
proportion of incident patients starting HD with a per-US from 54% (95% CI 43 to 64%) in 1996 to 28% (95%
manent access suggests that in the US there may be (1)CI 23 to 34%) in year 2000 (P  0.01).
overall decreased priority during the pre-ESRD period
for establishing a permanent access that can function for
DISCUSSION a patient’s first HD session, (2) more difficulties encoun-
tered from a surgical or technical standpoint in creatingThe direct comparison of vascular access use provided
a vascular access that successfully matures so as to beby DOPPS indicates large differences in vascular access
functional for the start of HD, (3) greater time/adminis-use in EUR compared with the US. EUR vascular access
trative constraints or patient reluctance, hindering earlyplacement is centered around AVF use with 66% of new
placement of permanent accesses, or (4) more frequentESRD patients starting HD with an AVF, and AVF use
failure of pre-ESRD evaluations to accurately estimaterising to 80% in EUR for all HD patients. Subgroup
onset of ESRD, leading to a delay in referral for vascular
analyses demonstrate that EUR practice is successful in
access placement. The net result of the current US vascu-
placing AVF at a high rate in a broad spectrum of pa- lar access practice is that 46% of US patients start HD
tients including older diabetic female patients with coro- with a catheter and have not had a permanent vascular
nary artery disease and/or peripheral vascular disease. access created prior to starting HD. This failure to place
Only 2% of EUR incident patients initiate HD with a a permanent access during the pre-ESRD period occurs
graft, indicating that grafts are seldom chosen for a pa- despite 55% of these patients without a permanent ac-
tient’s first permanent access in EUR. cess having seen a nephrologist30 days prior to ESRD.
In contrast to EUR, grafts are the predominant perma- The problem of incident patients starting HD without a
nent access in the US, serving 58% of prevalent patients, permanent access placed during the pre-ESRD period
and used by 24% of incident patients when starting HD. is not limited to the US. In EUR, approximately 25%
AVF are used by only 15% of US incident patients at of incident patients start HD with a temporary access and
initiation of HD, with AVF use increasing to 24% among have not had a permanent access placed prior to ESRD.
For this group of patients, 56% had seen a nephrologistprevalent patients in the US. These results from DOPPS
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30 days prior to ESRD. Both in the US and EUR, forming pre-operative vascular mapping with greater use
of brachiocephalic upper arm AVF [19, 21–23], and uti-further gains may be made in starting patients with a
permanent vascular access if a better understanding can lizing forearm superficial venous transposition [24]. No-
tably, Dr. Konner has achieved high levels of AVF usebe gained regarding the obstacles and factors that result
in patients not receiving a permanent access during the for a diverse patient population by performing detailed
mapping of patient vasculature prior to AVF placement,pre-ESRD period even though a nephrologist is seen
more than 30 days prior to ESRD. and employing a variety of different surgical approaches
to address the challenges posed by different clinical andAn important aspect of new ESRD patients starting
HD with a permanent access is the process and organiza- anatomical presentations [25, 26].
A noteworthy observation during the analysis of AVFtional structure of the referral network for placing vascu-
lar accesses. An expedient process of2 weeks from time versus graft use among new HD patients in EUR and
the US was the finding that the likelihood of AVF useof referral until access placement was associated with a
1.8-fold higher likelihood of new ESRD patients begin- was 40% lower in dialysis units in which surgery trainees
either assisted or performed permanent vascular accessning HD with a permanent vascular access. The number
of surgeons placing permanent accesses for a facility or placements (Table 5). Surgery trainees are used in ap-
proximately 34% of DOPPS dialysis units in both thewhether AVF cannulation typically occurs within two
months from the date of access creation, however, did US and EUR. These results suggest that graft placement
may be emphasized to a greater extent in surgical train-not appear to be associated with whether incident pa-
tients began dialysis with a permanent access. ing settings or that trainees are not adequately prepared
to create functioning AVF in a diverse patient popula-Previously, Hirth et al showed that AVF versus graft
use in the US strongly differed across some geographic tion. This may represent an opportunity for intervention
and improved vascular access outcomes for patients atregions and according to patient socioeconomic status
[17]. These analyses were adjusted for demographic and HD centers affiliated with surgical training programs.
In the US, 60% of new ESRD patients begin HD withcomorbid conditions, and suggested that factors beyond
a patient’s clinical presentation may play an important a catheter compared with 31% in EUR. One of the
negative effects for patients starting HD with a tempo-role in access placement decisions. Economic factors ap-
pear not to be a strong driving force for high graft use rary access is revealed in comparing AVF survival in
Figure 4. These results indicate that AVF and graft sur-in the US as suggested by two reports in which the annual
costs for use of grafts were found to be higher than for vival are substantially greater if used at the start of HD
rather than after a patient begins dialysis with a catheter.AVF (abstract; Collins et al, J Am Soc Nephrol 10:203A,
1999) [18]. Furthermore, for most patients, costs for ei- Although there may be patient characteristics not con-
trolled for in the survival analysis that may contributether type of access are covered by Medicare, and the
differences are small concerning reimbursements to phy- to the access survival differences in Figure 4, these results
of greater AVF and graft failure after catheter use couldsicians for placing grafts versus AVFs.
In the present study, a large variation of 0 to 100% also be due to (1) placement location of temporary cathe-
ters that adversely affect longevity of subsequently usedAVF use was seen among different dialysis units in the
US and EUR. AVF use in EUR facilities varied from AVF or grafts (abstract; Young et al, J Am Soc Nephrol
10:223A, 1999); (2) the AVF being used before they have39% to 100%, with 31% of EUR facilities having 90%
of their patients dialyzing with an AVF. In addition, fully matured [27]; or (3) changes/losses in biological
factors occurring once a patient begins hemodialysis withDOPPS data (not shown) and other reports indicate that
four of the five EUR countries have a smaller percent these changes leading to less favorable access maturation
resulting in higher access failure rates.of ESRD patients receiving peritoneal dialysis than in
the US [9, 11]. Therefore, the higher rates of AVF use Similar to several other studies [20, 28–33], our results
showed greater survival of AVF compared with graftsin EUR likely are not due to poor candidates for AVF
being steered to peritoneal dialysis. The higher rates of in the US. Furthermore, AVF survival was found to be
substantially better in EUR compared with the USAVF use seen in EUR suggest that in many EUR dialysis
units a process of vascular access care is in place leading (RR  0.49, P  0.0005). The reasons for this latter
effect will be evaluated in future analyses.to successful AVF placement in a very high proportion
of patients. A key question for future examination, in During the past 12 years, several reports including the
1997 DOQI Guidelines have recommended that prac-addition to a strong commitment to AVF placement, is
what processes have these dialysis units implemented in titioners avoid placing catheters in the subclavian vein to
minimize central vein stenoses and other complicationsorder to be highly successful in creating AVF for their
patients? Some dialysis units have reported substantial that may prohibit future placement of vascular accesses
on the side of the cannulation [2, 34–40]. Catheter place-increases in AVF use through organizational changes in
their approach to vascular access care [19, 20], per- ment in the subclavian vein differed considerably be-
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